Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic Implications
Anna N. Ligezka(Mayo Clinic in Florida), Éva Morava(Mayo Clinic), Hitoshi Yanaihara(Saitama Medical University), Christina Lam(Seattle Children's Hospital), William Brucker(Providence College), Karthik Muthusamy(Northwestern University), Kimiyo Raymond(Mayo Clinic in Arizona), Wasantha Ranatunga(Mayo Clinic), Akhilesh Pandey(Johns Hopkins University), Andrew C. Edmondson(Translational Therapeutics (United States)), Joel M. Reid(Children's Hospital of Philadelphia), David Cassiman, Bart Ghesquière(VIB-KU Leuven Center for Microbiology), Mayank Saraswat(Manipal Academy of Higher Education), Christin Johnsen(University of Washington), Devin Oglesbee(Mayo Clinic in Arizona), Austin Larson(Children's Hospital Colorado), Graeme Preston(Mayo Clinic), Kishore Garapati(Manipal Academy of Higher Education), Tamás Kozicz(Mayo Clinic in Florida), Silvia Radenkovic(VIB-KU Leuven Center for Cancer Biology), Wirginia Krzyściak(Jagiellonian University), Saadet Mercimek‐Andrews(University of Toronto), Ethan Perlstein, Renee M. McGovern(Mayo Clinic), Peter Witters(Universitair Ziekenhuis Leuven)
Cited by 57
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|803
A roadmap for interpreting 13C metabolite labeling patterns from cells
|Current Opinion in Biotechnology|2015|652